Spectrum Science
Independent
Address
2001 Pennsylvania Ave NW, Suite 200
Washington, District of Columbia 20006
Web Address
Year Founded
1996
Full-time Employees
181
Number of Clients
37
North American Revenue 2021
Full-time Employees 2021
Number of clients 2021
Offices
North America
4
Locations
Washington, DC
New York
Atlanta
Chicago
Executives & Senior Management
Jonathan Wilson
Owner & CEO
Michelle Gross
President
Senior Management
Jonathan Wilson
Owner & CEO
Michelle Gross
President
Dan Zaret
Chief Operating Officer
Rob Oquendo
Chief Innovation Officer
Justin Rubin
Chief Creative Officer
Michelle Strier
Chief Strategy Officer
Tom Goddard
President, GLOBALHealth PR
Andrea Sessler
Chief Human Resources Officer
Agency 100 Book Cover
Capabilities/Services Offered
Professional
Consumer
OTC
Direct Marketing
Media Planning
Med-ed
Med-Tech
Public Health
Data/Analytics
Digital
New Services
To meet the demands of today's marketplace and future needs of the industry, Spectrum continues to focus on innovating to achieve its health and science clients' goals. Much of this focus is thinking beyond digital, leveraging data and technology advancements that allow for increased tracking capabilities to create robust engagement strategies across multiple channels for connected, personalized experiences. In 2021, the agency formally established an engagement strategy knowledge center to better deliver connected experiences for our clients' audiences. New hire Patrick Richard, EVP, Engagement Strategy, leads Spectrum's efforts to connect with audiences in a technology-driven world, bolstering engagement capabilities to help clients find novel ways to drive audience engagement. For example, Spectrum works with Foundation Medicine (FMI) to address barriers healthcare professionals (HCPs) face learning about new programs or products. Using integrated closed-loop marketing to track activity, the team created flexible systems that implement the right technology to improve connectivity, create better experiences for HCPs and increase Foundation Medicine's sales. With EVP Patrick Richard's lead, Spectrum has brought in services including content and CX (customer experience) strategy, In addition, Spectrum hired EVP T.J. Stevens, who was previously at Johnson & Johnson, to lead technology strategy and innovation. Spectrum continues to evolve their proprietary data aggregation, insights and measurement tool Galileo6SM, with new modules to track performance dynamically and facilitate data-driven insights tailored for specific client needs. One module designed around clinical trial recruitment (CTR) allows teams to gauge end-to-end recruitment efforts though the CTR funnel, from awareness to a randomized trial patient. These efforts are led by another new hire, Suzanne Wiggins, SVP Research and Analytics, alongside longtime Spectrumite Brett Care, a key contributor to Galileo6's development, recently promoted to VP Measurement and Analytics. In addition to innovation and analytics, Spectrum built out its client services and program management functions to align with the evolving client work across advertising, medical communications and clinical trial recruitment.
Client Roster
Spectrum deeply values our clients' confidentially and does not disclose our full client roster. However, key clients include
AbbVie
Accent Therapeutics
Azurity Pharmaceuticals (formerly Arbor)
Bayer
Foundation Medicine
Heron Therapeutics
Horizon Therapeutics
Mirati
Neurocrine Biosciences
Takeda
Growth
2021 Growth from Existing Clients
53%
2021 Growth from New Clients
47%
Trends and Challenges
Diversity and inclusion
Talent acquisition/retention
Managing growth
Keeping up with pace of innovation
Client losses in the wake of pharma M&A
Replenishing new-business pipeline
Pandemic-related disruptions
Healthcare Marketing Trends
More personalization of communications
Need to create more/better content/experiences
Heightened focus on payers
Increased concern over drug pricing
Industry consolidation
Scrutiny around social media
Impact of empowered patients/consumers
Intensified focus on analytics/ROI/measurement
Decreased impact of sales forces
Regulatory changes
Programs that go “beyond the pill”
Evolution of EHRs
Emphasis on specialty drugs/high-science categories
Adopting a data-science culture
More digital experimentation
Seizing opportunities around cannabis
Working from home
Ongoing fallout from pandemic
Creative Samples
